Literature DB >> 17555759

Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy.

Rossella Marcucci1, Anna Maria Gori, Rita Paniccia, Cristina Giglioli, Piergiovanni Buonamici, David Antoniucci, Gian Franco Gensini, Rosanna Abbate.   

Abstract

A residual platelet reactivity (RPR) on antiplatelet therapy in patients with ischemic heart disease (IHD) has been reported to be associated with adverse clinical events by some Authors. However, scarce data are present on the clinical parameters associated with this phenomenon. No study, at our knowledge, was designed with the specific aim to examine the relationship between clinical characteristics and RPR. We sought to evaluate the clinical and laboratory characteristics associated with RPR in patients with IHD undergoing coronary revascularization on dual (aspirin plus clopidogrel) antiplatelet therapy. We included in the study 868 patients undergoing a coronary angiography: 386 with acute coronary syndromes undergoing a primary coronary revascularization and 482 IHD patients scheduled to undergo an elective coronary angiography. We measured platelet function by both platelet aggregation with two agonists [0.5 mg/mL arachidonic acid (AA); 2 and 10 microM adenosine 5'-diphosphate (ADP)] and a point-of-care assay (PFA-100) on venous blood samples collected within 24 h from the end of the procedure. In patients with acute coronary syndromes and elective PCI diabetes is independently associated with RPR [group A: OR=2.9 (1.5-5.7) by 10 microM ADP, OR=5.3 (1.1-27.8) by PFA-100; group B: OR=4.0 (1.6-10.0) by 10 microM ADP]; reduced left ventricular systolic function [OR=3.7 (2.2-6.5) by AA-PA, OR=2.7 (1.6-4.6) by PFA-100], chronic use of aspirin [OR=0.2 (0.1-0.4) by AA-PA, OR=0.3 (0.2-0.5) by PFA-100] and loading dose of clopidogrel [OR=0.2 (0.06-0.5) by 10 microM ADP] were independent variables significantly associated with RPR in patients undergoing elective PCI. In addition, inflammatory status was found to be significantly associated with RPR in both groups of patients. These results provide indications for the selection of patients for whom the evaluation of platelet reactivity could be useful.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17555759     DOI: 10.1016/j.atherosclerosis.2007.04.048

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  5 in total

1.  Efficacy and safety of individually tailored antiplatelet therapy in patients with acute coronary syndrome after coronary stenting: a single center, randomized, feasibility study.

Authors:  Hong-Chang Zhu; Yi Li; Shao-Yi Guan; Jing Li; Xiao-Zeng Wang; Quan-Min Jing; Zu-Lu Wang; Ya-Ling Han
Journal:  J Geriatr Cardiol       Date:  2015-01       Impact factor: 3.327

2.  Von Willebrand factor antigen predicts response to double dose of aspirin and clopidogrel by PFA-100 in patients undergoing primary angioplasty for ST elevation myocardial infarction.

Authors:  Jacopo Gianetti; Maria Serena Parri; Francesca Della Pina; Federica Marchi; Endrin Koni; Alberto De Caterina; Stefano Maffei; Sergio Berti
Journal:  ScientificWorldJournal       Date:  2013-12-19

3.  Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE).

Authors:  Michal Droppa; Dimitri Tschernow; Karin A L Müller; Elli Tavlaki; Athanasios Karathanos; Fabian Stimpfle; Elke Schaeffeler; Matthias Schwab; Alexander Tolios; Jolanta M Siller-Matula; Meinrad Gawaz; Tobias Geisler
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

4.  Determinants to optimize response to clopidogrel in acute coronary syndrome.

Authors:  Betti Giusti; Anna Maria Gori; Rossella Marcucci; Claudia Saracini; Anna Vestrini; Rosanna Abbate
Journal:  Pharmgenomics Pers Med       Date:  2010-04-08

Review 5.  Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs.

Authors:  Giuseppe Patti; Ilaria Cavallari; Felicita Andreotti; Paolo Calabrò; Plinio Cirillo; Gentian Denas; Mattia Galli; Enrica Golia; Ernesto Maddaloni; Rossella Marcucci; Vito Maurizio Parato; Vittorio Pengo; Domenico Prisco; Elisabetta Ricottini; Giulia Renda; Francesca Santilli; Paola Simeone; Raffaele De Caterina
Journal:  Nat Rev Cardiol       Date:  2019-02       Impact factor: 32.419

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.